Low-Dose Naltrexone Overdose & Accidental Excess Dose: What to Do and What to Expect

Why LDN Overdose Is Rare but Still Worth Understanding

Low-dose naltrexone is typically compounded at doses between 0.5 mg and 4.5 mg, a small fraction of the 50 mg FDA-approved tablet used for alcohol and opioid use disorders. That gap, roughly tenfold or more, creates a wide safety buffer. Accidental ingestion of multiple LDN capsules, while unpleasant, does not typically produce the organ-threatening toxicity seen with opioid or benzodiazepine overdoses.

Naltrexone has a track record of tolerating single doses well above the standard 50 mg tablet in clinical pharmacology research, with nausea and dysphoria as the main limiting side effects rather than organ failure (FDA prescribing information). Anyone who needs the exact historical dosing figures from those early studies should confirm them against the current label rather than relying on a secondhand number. Animal toxicology testing has also found a wide margin between typical doses and doses associated with toxicity in rodent models, though a lethal dose in humans has not been established. None of this means an excess dose is harmless. It means the danger from LDN overconsumption comes mainly from receptor-level effects and drug interactions, not direct organ damage.

Two small trials at Stanford, a pilot study of about 10 patients using 4.5 mg nightly LDN (Younger and Mackey, 2009) and a larger placebo-controlled crossover trial in roughly 30 women with fibromyalgia (Younger et al., 2013), found meaningful reductions in pain scores at that specific low dose. Neither trial tested whether higher doses worked better, and the pharmacology explains why more is not expected to help: above the LDN range, the brief receptor blockade that appears to drive the effect turns into a longer, more complete blockade that does not produce the same rebound benefit.

How Low-Dose Naltrexone Works: The Mechanism Behind the Risk

LDN's pharmacology explains both its therapeutic effects and the specific dangers of overdose. At doses of 1 to 4.5 mg, naltrexone briefly and partially blocks mu-opioid receptors for roughly 4 to 6 hours. This transient blockade is thought to trigger a compensatory increase in the body's own opioid-like signaling (endorphins, enkephalins) and increased receptor sensitivity during the rebound phase.

A second mechanism, proposed in review literature on LDN's anti-inflammatory potential, involves toll-like receptor 4 (TLR4) antagonism on glial cells (Younger et al., 2014, Clin Rheumatol). By this hypothesis, naltrexone dampens microglial activation and the release of pro-inflammatory signaling molecules such as interleukin-6 and tumor necrosis factor-alpha, independent of the opioid receptor pathway. This proposed mechanism is one reason LDN has been tried off-label in conditions like fibromyalgia, Crohn's disease, and multiple sclerosis, though controlled human trials quantifying the effect on inflammatory markers remain limited.

At overdose-level doses (above 10 to 50 mg), the brief, pulsatile receptor blockade that makes LDN therapeutically useful becomes a sustained, near-complete blockade. The rebound endorphin surge does not occur in the same way. Instead, the person experiences prolonged opioid-system suppression, which manifests as dysphoria, pain amplification, and, in opioid-dependent individuals, acute withdrawal.

Recognizing Symptoms of an LDN Excess Dose

The symptom profile depends on how much was taken and whether opioids are onboard. Expect a dose-dependent spectrum.

At 2 to 5 times the prescribed LDN dose (roughly 10 to 25 mg): Most people report nausea, abdominal cramping, headache, and anxiety within 30 to 90 minutes. These symptoms are self-limiting and generally resolve within 12 to 24 hours as the drug clears. A study of naltrexone side effects in alcohol-dependent patients receiving 50 mg daily found nausea in about 10 percent and headache in about 7 percent of participants (Croop et al., Arch Gen Psychiatry 1997), at doses far higher than any plausible LDN dosing error.

At 50 mg or above (full-dose territory): Symptoms can include sustained nausea, vomiting, dizziness, anxiety, and joint pain. The FDA label does not describe a distinctly different adverse event pattern at doses moderately above 50 mg, though gastrointestinal symptoms tend to be more pronounced.

In people concurrently taking opioids: This is the scenario that creates a genuine emergency. Even a small increase above the LDN dose (for instance, accidentally taking 10 mg instead of 4.5 mg) can precipitate acute opioid withdrawal in someone on concurrent opioid therapy. Symptoms include severe abdominal cramping, profuse diarrhea, a fast heart rate, sweating, agitation, and muscle aches. SAMHSA's clinical guidance on medications for opioid use disorder describes precipitated withdrawal as an acute and highly distressing syndrome that typically peaks within the first couple of hours and can continue for one to three days (SAMHSA TIP 63).

Decision Framework: What to Do About a Suspected Excess Dose

This is not a substitute for Poison Control or emergency care. It is a way to organize the two variables that actually change what you should do: opioid status and dose size.

First question: is the person taking any opioid medication right now? This includes tramadol, codeine-containing cough syrup, buprenorphine, methadone, or any prescription pain medication.

• Yes: treat this as a potential emergency regardless of how small the excess dose seems. Even a modest increase above the prescribed LDN dose can precipitate acute opioid withdrawal in someone on opioids. Call 911 or go to the nearest emergency department. Tell clinicians exactly when the naltrexone was taken, since it affects how they manage pain and withdrawal for the next 24 to 72 hours.
• No: move to the second question.

Second question, for someone not taking opioids: how much was taken relative to the prescribed dose?

• A double dose or similar small excess (for example, 9 mg instead of 4.5 mg): generally low risk. Expect possible nausea, headache, or stomach upset for 12 to 24 hours. Hydrate, rest, and skip the next scheduled dose. Call Poison Control (1-800-222-1222) if symptoms are severe or you are unsure.
• A larger excess, roughly 10 to 50 mg: call Poison Control for a real-time risk assessment. Home monitoring with fluids and anti-emetics is usually enough, but persistent vomiting that prevents hydration for more than 4 hours needs medical evaluation.
• 50 mg or more, or any amount in a child, someone with known liver cirrhosis, or someone with a resting heart rate above 120 bpm: go to the emergency department rather than managing at home.

Exceptions that override the default pathway regardless of dose: pregnancy, known liver disease, age under 12, or uncertainty about what was actually ingested, for example if a compounding error is suspected and the capsules may not match the labeled strength. In any of these situations, contact Poison Control or a clinician rather than relying on the dose-based thresholds above.

After the immediate situation is resolved: tell the prescriber and the compounding pharmacy what happened. This is how dosing errors and compounding errors get caught before they recur, and it may lead to a safer dispensing format such as blister packaging.

Emergency clinicians managing a significant excess dose or precipitated withdrawal typically rely on supportive care: IV fluids for dehydration, ondansetron for vomiting, clonidine for autonomic symptoms like sweating and rapid heart rate, and benzodiazepines for severe agitation. There is no specific antidote for naltrexone itself.

The Opioid Interaction: Why This Is the Real Danger

The most clinically significant overdose scenario is not someone accidentally taking a handful of extra LDN capsules. It is a patient on chronic opioid therapy who takes even a modestly elevated naltrexone dose. Naltrexone's label warns that it can precipitate withdrawal in people who are physically dependent on opioids, and that symptoms can be severe enough to require hospitalization.

Case reports and clinical case series describe precipitated withdrawal after naltrexone exposure in patients whose opioid washout period was incomplete, sometimes requiring inpatient supportive care (Mannelli et al., 2014, on pharmacological approaches to naltrexone induction, J Addict Med). Those reports generally involve full-dose naltrexone, but the underlying pharmacology, a mu-opioid antagonist displacing opioid molecules from the receptor, applies at any naltrexone dose in someone who is opioid-dependent. The difference is one of degree, not of kind.

Patients transitioning from opioid therapy to LDN are typically advised to complete a washout period, commonly 7 to 10 days for short-acting opioids and 10 to 14 days for long-acting formulations like methadone, before starting naltrexone. General naltrexone prescribing guidance from the American Society of Addiction Medicine calls for a confirmed negative urine drug screen, and often a naloxone challenge test, before starting naltrexone at any dose (ASAM National Practice Guideline). The Endocrine Society does not publish LDN-specific transition guidance, so these washout intervals reflect general addiction medicine practice rather than an LDN-specific standard.

Hepatotoxicity Concerns: Separating Fact from Label Language

The naltrexone prescribing label carries a bolded hepatotoxicity warning based on early trials that used 300 mg daily, six times the standard 50 mg dose, mostly in patients being studied for obesity, where transaminase elevations were observed (FDA prescribing information). That warning is accurate for the dose it was studied at, but it has generated disproportionate concern among LDN users taking a small fraction of that amount.

A 2018 review by Toljan and Vrooman summarizing the published LDN literature reported no clinically significant liver enzyme elevations in the small studies and case series available at doses of 1.5 to 4.5 mg (Toljan & Vrooman, 2018). That is reassuring, but it reflects a review of limited existing data, not a large controlled safety trial, and no long-term, adequately powered study of LDN and liver function has been published. Baseline and periodic liver function testing remains a reasonable precaution, especially for anyone with preexisting liver disease.

For a one-time accidental excess dose in the 10 to 50 mg range, the hepatotoxicity signal associated with sustained 300 mg daily dosing does not apply directly. A single excess dose is not expected to cause acute liver injury in someone without underlying liver disease. Anyone with known hepatic impairment who takes an excess dose should still contact their prescriber, since naltrexone clearance is slower when the liver is not working normally, which prolongs every other effect of the drug as well.

Duration of Effects After an Excess Dose

Naltrexone's plasma half-life is about 4 hours, but its main active metabolite, 6-beta-naltrexol, has a half-life of roughly 12 hours. PET imaging studies of opioid receptor occupancy found that a single 50 mg dose of naltrexone produced more than 90 percent mu-opioid receptor blockade at 24 hours, declining to about 50 percent blockade by 48 hours (Lee et al., J Nucl Med 1988).

For someone who accidentally takes 10 to 20 mg of LDN, expect opioid receptor effects to persist for roughly 24 to 36 hours. At 50 mg, plan for 48 to 72 hours of meaningful blockade. This has a direct practical consequence: anyone who needs emergency opioid pain control (after a traumatic injury, for example) during this window will get a markedly reduced response from standard opioid doses. Tell emergency staff about the naltrexone exposure so they can use non-opioid alternatives such as ketorolac, ketamine, or a regional nerve block during the blockade window.

Preventing Accidental Excess Doses

Most LDN overdose events stem from one of three scenarios: forgetting whether a dose was taken and doubling up, confusion between LDN capsules and another similarly sized medication, or a compounding error that produces capsules with higher-than-intended drug content.

Practical prevention measures include using a pill organizer with labeled days, requesting a distinct capsule color for LDN from your compounding pharmacy, and keeping compounded LDN in a separate, clearly labeled container. USP General Chapter 795 sets compounding standards for nonsterile preparations like LDN capsules, including expectations around potency verification, and the FDA's compounding policy page describes the broader regulatory framework compounding pharmacies operate under (FDA compounding policy). It is reasonable to ask your compounding pharmacy whether it performs routine third-party potency testing.

If a compounding error is suspected, retain the remaining capsules and report the event to the state board of pharmacy and the FDA's MedWatch program. Compounding errors, while uncommon, represent one of the higher-risk pathways to unintentional naltrexone overdose in the LDN population, precisely because the person has no way to know the dose was wrong until symptoms appear.

Special Populations: Children, Older Adults, and Liver Disease

Accidental pediatric ingestion requires immediate Poison Control contact regardless of dose. No pediatric safety data exist for naltrexone at any dose in children under age 6, and there is no published pediatric guidance specific to accidental naltrexone ingestion, so any exposure in a young child should be managed conservatively with clinical observation.

In older adults, naltrexone clearance is reduced to some degree due to age-related declines in hepatic blood flow and metabolic enzyme activity, though exact figures for LDN dosing have not been established. An accidental excess dose in an older adult will likely produce longer-lasting receptor blockade and more pronounced gastrointestinal side effects than the same dose would in a younger adult. The Beers Criteria do not list naltrexone as a potentially inappropriate medication for older adults, but they also do not provide dose-adjustment guidance specific to LDN levels (American Geriatrics Society, 2023).

People with known liver disease (Child-Pugh class B or C) should exercise extra caution. A single-dose LDN exposure is unlikely to cause acute liver injury, but naltrexone clearance is prolonged in hepatic impairment, which extends the duration of every effect of the drug, including receptor blockade and gastrointestinal disturbance.

When to Go to the Emergency Department

Not every LDN excess dose needs emergency care. Go to the ED if any of the following apply: the person takes opioid medication of any kind, the estimated ingested dose is 50 mg or more, vomiting has prevented oral hydration for more than 4 hours, resting heart rate is above 120 bpm, the person is a child under 12, or the person has known liver cirrhosis. For a non-opioid adult who accidentally took a double dose of LDN (about 9 mg), home monitoring with fluids and a call to Poison Control is generally appropriate.

As with any compounded medication, it is worth asking your prescriber in advance what to do if you take too much, since compounded LDN does not come with the same standardized patient counseling materials as a commercially manufactured drug.